请使用支持JavaScript的浏览器!
主营:分子类,蛋白类,抗体类,生化类试剂
℡ 4000-520-616
℡ 4000-520-616
asuragen/QuantideX® qPCR BCR-ABL minor Kit (RUO)/60/49640
产品编号:49640
市  场 价:¥0.00
场      地:美国(厂家直采)
产品分类: 生化试剂>其他>>
联系QQ:1570468124
电话号码:4000-520-616
邮      箱: info@ebiomall.com
美  元  价:待定
品      牌: asuragen
公      司:asuragen
公司分类:
asuragen/QuantideX® qPCR BCR-ABL minor Kit (RUO)/60/49640
商品介绍

QuantideX® qPCR BCR-ABL minor Kit (RUO)

BCR-ABL blood cancer cellsThe QuantideX® qPCR BCR-ABL minor Kit (RUO) is a clinical research tool enabling ultra-sensitive and precise detection of BCR-ABL1 minor fusion transcripts (e1a2) from whole blood specimens. Building on the simple workflow and best-in-class sensitivity established with the FDA-cleared QuantideX® qPCR BCR-ABL IS Kit, the minor Kit allows labs and clinical researchers to examine the biology of disease for this very rare but distinct leukemic variant with unprecedented ease.

Features & Benefits

The QuantideX qPCR BCR-ABL minor Kit (RUO) delivers high performance through unmatched sensitivity and optimized laboratory efficiency.

Reduced ComplexityEase-of-data analysis and reporting:

  • Leverages the QuantideX® qPCR BCR-ABL IS Kit workflow concept for streamlined implementation
  • Included software provides automated calculation of BCR-ABL1/ABL1 % ratio and eliminates the need for manual calculation

Optimized WorkflowValuable operator hands-on time has been significantly reduced through:

  • Multiplexed design amplifies and detects both fusion and control gene in the same reaction
  • All-inclusive reagents sourced and quality controlled together from a single vendor
  • Pre-mixed reagents allow fewer pipetting steps in mastermix preparation

Quality PerformanceDetecting BCR-ABL1 minor transcripts robustly and reliably with a highly sensitive assay:

  • Ultra-sensitive Limit of Detection (LOD): Log reduction of 4.61 (0.0025% ratio)
  • Increased analytical sensitivity without compromising analytical specificity: incorporates Limit of Blank (LOB) to prevent miscalling of non-leukemic low positives
  • Armored RNA®-based standards provide true RNA quantification

Analytical Characteristics

  • Reproducible: Proven sensitivity based on rigorous testing criterion (Table 1)
  • Precise: Minimal variability across entire dynamic range of BCR-ABL1/ABL1 % ratios (Table 2)
  • Streamlined: Multiplexed design yields workflow and cost efficiencies (Figure 1)

Proven Sensitivity Based on Rigorous Testing CriterionTable 1: LOD as determined by CLSI EP17-A2 guidelines by testing human RNA and cell line dilutions spanning lots, batch runs, days, operators and instruments.

Minimal Variability across Entire Dynamic Range

Table 2: Assay precision determined by testing 4 different log reduction (LR) levels in human RNA, using 2 operators and 8 runs for a total of 192 data points.

Multiplexed Design Yields Workflow and Cost Efficiency  

Figure 1: Comparison of a plate layout for 8 sample run on Asuragen plate (left) and an alternate non-multiplex assay (right): 19 reactions for Asuragen setup vs. 52 reactions on a non-multiplex assay setup

Ordering

Product NameNumber of ReactionsCatalog Number
QuantideX® qPCR BCR-ABL minor Kit (RUO)6049637

T 512.681.5200 or 877.777.1874 F 512.681.5202 E orders@asuragen.com

View Sales Contacts

QuantideX® qPCR BCR-ABL minor Kit

The BCR-ABL1 minor breakpoint (e1a2) constitutes a rare but distinct leukemic variant and accurate detection and quantitation of these fusion transcripts are paramount to improving outcomes for all chronic myeloid leukemia (CML) patients. The QuantideX® qPCR BCR-ABL minor Kit, an in vitro diagnostic (IVD) assay, enables ultra-sensitive detection of BCR-ABL1 minor fusion transcripts from whole blood specimens.

Features & Benefits

The QuantideX qPCR BCR-ABL minor Kit marries improved efficiency with unprecedented sensitivity, empowering labs to assess the deepest molecular responses in patients harboring the minor breakpoint with the ease-of-use they’ve come to expect from Asuragen.

Reduced ComplexityEase-of-data analysis and reporting:

  • Shares a common workflow with the QuantideX® qPCR BCR-ABL IS Kit to reduce training burden and streamline test implementation
  • Included software provides automated calculation of BCR-ABL1/ABL1 % ratio and the ability to report BCR-ABL Major on both the International Scale (IS) and copy number*

Optimized WorkflowValuable operator hands-on time has been significantly reduced through:

  • Multiplexed design amplifies and detects both fusion and control gene in the same reaction
  • All necessary RT and qPCR reagents sourced and quality controlled together from a single vendor
  • Pre-mixed reagents allow fewer pipetting steps in mastermix preparation

Quality PerformanceDetecting BCR-ABL1 minor transcripts robustly and reliably with a highly sensitive assay:

  • Ultra-sensitive Limit of Detection (LOD): Log reduction of 4.61 (0.0025% ratio)
  • Increased analytical sensitivity without compromising analytical specificity: incorporates Limit of Blank (LOB) to prevent miscalling of non-leukemic low positives
  • Armored RNA®-based standards provide true RNA quantification

Download Brochure

Analytical Characteristics

  • Reproducible: Proven sensitivity based on rigorous testing criterion (Table 1)
  • Precise: Minimal variability across entire dynamic range of BCR-ABL1/ABL1 % ratios (Table 2)
  • Streamlined: Multiplexed design yields workflow and cost efficiencies (Figure 1)

Proven Sensitivity Based on Rigorous Testing CriterionTable 1: LOD as determined by CLSI EP17-A2 guidelines by testing human RNA and cell line dilutions spanning lots, batch runs, days, operators and instruments.

Minimal Variability across Entire Dynamic Range

Table 2: Assay precision determined by testing 4 different log reduction (LR) levels in human RNA, using 2 operators and 8 runs for a total of 192 data points.

Multiplexed Design Yields Workflow and Cost Efficiency  

Figure 1: Comparison of a plate layout for 8 sample run on Asuragen plate (left) and an alternate non-multiplex assay (right): 19 reactions for Asuragen setup vs. 52 reactions on a non-multiplex assay setup

Ordering

Product NameNumber of ReactionsCatalog Number
QuantideX® qPCR BCR-ABL minor Kit6049640

T +1 512.681.5200 or +1 877.777.1874 F +1 512.681.5202 E orders@asuragen.com

View Sales Contacts
品牌介绍

asuragen的AmplideX®PCR / CE C9orf72试剂盒

C9orf72主网页图像小AmplideX PCR / CE C9orf72试剂盒(RUO)是用于检测C9orf72基因中GGGGCC重复序列的研究产品。这些试剂提供了基于重复引物PCR(RP-PCR)设计的单管PCR方法,以分析C9orf72基因中的重复序列  。


 


特点与优势

分析特性

订购方式

特点与优势

Asuragen已经建立了市场领先的技术,可以可靠地扩增和分析FMR1基因中CGG三联体重复序列。AmplideX PCR / CE C9orf72 试剂盒(RUO)是该技术向神经遗传学领域的扩展。该试剂盒为临床和药学研究人员提供了一种可靠且可重现的方法,可用于C9orf72基因中六核苷酸重复扩增的高分辨率基因分型  ,这对额颞叶痴呆(FTD)引起了越来越多的关注。疾病-肌萎缩性侧索硬化症(ALS)。



通过以下方法简化了 C9orf72基因的复杂度分析:


实施专有的二合一PCR解决方案以扩增富含GC的区域

单一来源的试剂盒,包含C9orf72  重复扩增所需的所有PCR试剂

简化的工作流程,动手时间最短

优化的工作流程

通过以下方式大大减少了宝贵的操作员动手时间:


单一PCR反应可用于上浆和筛选

直接将PCR产物注入(无需PCR清理)到毛细管电泳平台

减少对Southern blot分析的需求

质量绩效

执行C9orf72一个具有更高的灵敏度和准确度nalysis:


等位基因大小的长度提高了五倍:精确定量多达145个重复序列

检测到大于145个重复的等位基因

揭示低水平的镶嵌和次要等位基因


自营商城图标
厂家直采
全球直采 正品优价
正品保障图标
正品保障
厂家直发 有线跟踪
解放采购图标
正规清关
CIF100%正规报关,提供发票
及时交付图标
及时交付
限时必达 不达必赔